Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance.
about
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistanceLack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseViability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapyCrystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirStructure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugsBMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsSecond locus involved in human immunodeficiency virus type 1 resistance to protease inhibitorsHuman immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogsImpaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitorsStatistical potentials for fold assessment.Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.Prediction of the binding energy for small molecules, peptides and proteins.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsAtazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesSensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisA secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation.A prospective study of predictors of adherence to combination antiretroviral medicationEmergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detectionIn vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutantsViremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern IndiaResistance to human immunodeficiency virus type 1 protease inhibitors.Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system.Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants.Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases.Effectiveness of commercial inhibitors against subtype F HIV-1 protease.Incorporating target heterogeneity in drug designEffects of somatic mutations on CDR loop flexibility during affinity maturation
P2860
Q27628785-82483C87-8754-4877-957C-6518AEE8DB79Q27637329-B8C8A389-E610-41A1-9A89-74A1EB748A10Q27640250-28768828-B913-418C-9F13-D147E1783DAEQ27641090-2362FCFF-3CD4-438A-9B5B-055BD2A258E0Q27645052-E25459E5-CF97-4D3C-8AF5-586D8750C7D5Q27748828-1185D0ED-A791-4AD9-B7E7-ECF537726B93Q28344472-EE764AF9-FC95-45E6-99D4-0E659C1BA5F2Q28378860-23E23B20-CCD9-4ED2-9521-261D60185943Q28379226-748E5F3A-84F5-479C-86EC-3B3CB09FF718Q28379411-89744064-7476-4649-A452-048F3A287C0BQ30329417-D3AE7000-CC25-44EE-960D-0426622E9877Q33592125-48DB4CE7-34FD-480B-8CBF-C27F26D2A8B7Q33682938-6EC10E34-C2F9-4452-B3BC-310556C7BD67Q33770040-34BF1C43-2E59-46BF-934F-44BF32A46A35Q33935276-4D8D70D4-E3A1-426C-BD2E-59073116C016Q33995100-40876FF0-DF3F-454B-BA88-EACACD5C2C91Q34010283-4D956A2B-082B-4195-9E07-ACA173839C8CQ34594475-27CCA9A1-D551-4F46-B72D-E9143AD52D24Q34743444-5211FDC9-DC21-48C7-904A-C7422B010C0CQ35129066-E8423B14-0671-42E1-A71F-695B511D3EEEQ35857907-B2DA2625-F990-4B7B-A3A2-7EDEC9B31D8DQ35927934-129ADE3A-EE08-4E46-B977-35A327901B24Q36034959-9F476FA6-F35A-4027-AD27-6116B8E5262EQ36607906-E9E7B40B-3343-4493-9B0C-A0F68E50A575Q39559316-E8D82249-FF71-4C96-A238-FFDE123CD7E4Q39579408-E7AD3241-BFAF-4BBF-8E9B-07C3E90699CEQ41679805-A1C71983-047A-45DF-9EE6-22BED707F5DCQ42552199-F3F65534-05A6-44F4-AA99-962D2D647A56Q42845853-6CCCB56F-0A60-43A9-8068-C9802BD233E7Q44103766-FF1B0136-58D2-4EC0-B1E8-DFFCFF4974EDQ45765743-2B6FDBE2-FCB8-4DFD-9244-23F0594C8F5BQ45770160-B0CABA78-29CE-446C-B894-190B8BFCF071Q45790361-30A40D57-429B-44DF-B2A6-3CC2C95EF38FQ46339842-5528D4C5-C54E-46DE-A632-810CC86CFD2CQ58023123-AAF2FD58-DC0B-40D6-B8BA-A0049581CE44Q58043781-F79ACD8A-E30E-4A6E-98EF-B837AD3B914C
P2860
Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Effect of point mutations on t ...... lationship to drug resistance.
@en
type
label
Effect of point mutations on t ...... lationship to drug resistance.
@en
prefLabel
Effect of point mutations on t ...... lationship to drug resistance.
@en
P2093
P356
P1433
P1476
Effect of point mutations on t ...... lationship to drug resistance.
@en
P2093
Foundling S
Heinrikson RL
Leelamanit W
Raterman D
Thaisrivongs S
P304
P356
10.1021/BI00004A007
P407
P577
1995-01-01T00:00:00Z